CTX-320 is under clinical development by CRISPR Therapeutics and currently in Phase I for Atherosclerosis. According to GlobalData, Phase I drugs for Atherosclerosis have a 64% phase transition ...

So you’ve got a new computer. Awesome! That humble metal box is the key to a wide world of potential. It can help you with everything from juggling your finances to keeping in touch with your ...

RWKV is an RNN with transformer-level LLM performance. It can be directly trained like a GPT (parallelizable). So it's combining the best of RNN and transformer - great performance, fast inference, ...

A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has achieved “remarkable” improvements in patients with beta thalassaemia and sickle cell disease in an early-stage trial ...